Relative risk of PTLDs by age at transplantation and combination of major risk factors
| Model . | Age younger than 50 y . | Age 50 y or older . | Age 50 y or older versus younger than 50 y . | ||||
|---|---|---|---|---|---|---|---|
| Patients . | PTLD . | RR (95% CI) . | Patients . | PTLD . | RR (95% CI) . | RR (95% CI) . | |
| No. of major risk factors*† | |||||||
| No risk factors | 21 686 | 29 | 1.0 (referent group) | 799 | 6 | 6.7 (2.5-15) | 6.7 (2.5-15) |
| 1 risk factor | 2871 | 29 | 9.3 (5.5-16) | 113 | 4 | 46 (14-118) | 5.0 (1.5-13) |
| 2 or more risk factors | 1399 | 55 | 45 (29-75) | 33 | 4 | 237 (68-637) | 5.1 (1.5-13) |
| GVHD status‡ | |||||||
| No GVHD | 13 938 | 53 | 1.0 (referent group) | 424 | 8 | 8.1 (3.5-16) | 8.1 (3.5-16) |
| Acute or chronic GVHD | 12 018 | 60 | 2.1 (1.4-3.1) | 521 | 6 | 7.0 (2.7-15) | 3.3 (1.3-7.2) |
| Model . | Age younger than 50 y . | Age 50 y or older . | Age 50 y or older versus younger than 50 y . | ||||
|---|---|---|---|---|---|---|---|
| Patients . | PTLD . | RR (95% CI) . | Patients . | PTLD . | RR (95% CI) . | RR (95% CI) . | |
| No. of major risk factors*† | |||||||
| No risk factors | 21 686 | 29 | 1.0 (referent group) | 799 | 6 | 6.7 (2.5-15) | 6.7 (2.5-15) |
| 1 risk factor | 2871 | 29 | 9.3 (5.5-16) | 113 | 4 | 46 (14-118) | 5.0 (1.5-13) |
| 2 or more risk factors | 1399 | 55 | 45 (29-75) | 33 | 4 | 237 (68-637) | 5.1 (1.5-13) |
| GVHD status‡ | |||||||
| No GVHD | 13 938 | 53 | 1.0 (referent group) | 424 | 8 | 8.1 (3.5-16) | 8.1 (3.5-16) |
| Acute or chronic GVHD | 12 018 | 60 | 2.1 (1.4-3.1) | 521 | 6 | 7.0 (2.7-15) | 3.3 (1.3-7.2) |
RR indicates relative risk; PTLD, posttransplantation lymphoproliferative disorder; CI, confidence interval; and ATG, antithymocyte globulin.
Major PTLD risk factors are defined as follows: (1) T-cell depletion using selective T-cell depletion methods (see definitions in Table 3), (2) use of ATG therapy to prevent or treat acute graft-versus-host disease, (3) 2+ HLA antigen–mismatched sibling/relative, or unrelated donor, accompanied by selective T-cell depletion or ATG therapy.
Adjusted for acute and chronic GVHD, T-cell depletion using broad lymphocyte depletion methods, and second transplantation.
Adjusted for major risk factors noted above, T-cell depletion using broad lymphocyte depletion methods, and second transplantation.